ArticleBMC cancer2025
Low-exhaustion peripheral circulating γδ T cells serve as a biomarker for predicting the clinical benefit rate of non-small cell lung cancer (NSCLC) patients to chemotherapy or targeted therapy: a single-center retrospective study.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- γδ T cell exhaustion is associated with obesity in individuals with type 2 diabetes.International journal of obesity (2005) · 2026Article
- Machine learning-driven identification of shared and disease-specific mitochondria-related genes in COPD, NSCLC, and NSCLC with COPD.iScience · 2026Article
- Distribution and function of human long-lasting T cells in aging and non-small cell lung cancer.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundMultiple studies have demonstrated that the abundance and functionality of γδ T cells are favorable prognostic indicators for prolonged survival in cancer patients. However, the association between the immunophenotype of circulating γδ T cells and the therapeutic response in NSCLC patients undergoing chemotherapy or targeted therapy remains unclear.
methodsPatients with EGFR wild-type (EGFR-WT) or mutant (EGFR-Mut) non-small cell lung cancer (NSCLC), diagnosed between January 2020 and January 2024, were included in this study. Clinicopathological characteristics, treatment regimens, and follow-up data were retrospectively collected. Peripheral blood samples from 52 NSCLC patients were analyzed for the immunophenotypes of αβ T cells and γδ T cells using full-spectrum flow cytometry.
resultsNo significant differences were observed in the proportions of αβ T cells or γδ T cells, nor in the expression of immune exhaustion markers, between epidermal growth factor receptor wild-type and mutant NSCLC patients. Notably, NSCLC patients with a high clinical benefit rate (responder, R) exhibited a higher proportion of circulating Vδ2 T cells compared to non-responders (NR), in both EGFR-Mut (NR vs. R, P = 0.0437) and EGFR-WT groups (NR vs. R, P = 0.0180). Additionally, the expression of the immune exhaustion marker PD-1 on Vδ2 T cells was significantly lower in the responder group (NR vs. R, EGFR-Mut, P = 0.0050; EGFR-WT, P = 0.0180). Moreover, responder patients exhibited elevated levels of TNF-α compared to non-responders, irrespective of EGFR mutation status (NR vs. R, EGFR-Mut, P = 0.0055; EGFR-WT, P = 0.0007).
conclusionsThese findings collectively suggest that circulating Vδ2 T cells with low levels of immune exhaustion are critical contributors to the effectiveness of chemotherapy and targeted therapies in NSCLC. Targeting Vδ2 T cells may represent a promising strategy for enhancing therapeutic clinical benefit rates in NSCLC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.